close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

6.170 +0.280 (+4.75%)
Official Closing Price Updated: 8:00 PM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
41 42 Next >
News headline image
Psychedelic Stocks Continue To Decline In May ↗
The 10 companies in our Psychedelic Compounds-Based Drug Stocks Index are clinical-stage startups still in the product research and development of novel compounds with no products and no revenue. 
Via Talk Markets
News headline image
TripAdvisor, Field Trip Health Among Top Psychedelic Movers Of Today ↗
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 9.40% at $0.16 
Via Benzinga
Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Proprietary CYB003 Set to Move Forward in First-in-Human Phase 1/2a Clinical Trial
Via Investor Brand Network
News headline image
GH Research, Intelgenx Technologies Among Top Psychedelic Movers Of Today ↗
GAINERS: TripAdvisor (NASDAQ:TRIP) shares closed up 5.09% at $25.80 LOSERS: 
Via Benzinga
Research Finds That Mushrooms May Have Their Own Language
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Preclinical Study Findings to Be Showcased at Global Event Focused on Psychedelic-Assisted Therapy
Via Investor Brand Network
News headline image
Cybin Announces CYB003 Poster to be Presented at the ‘From Research to Reality’ Global Summit on Psychedelic-Assisted Therapies and Medicine
From Cybin Inc.
Via Business Wire
News headline image
Intelgenx Technologies, Field Trip Health Among Top Psychedelic Movers Of Today ↗
GAINERS: Intelgenx Technologies (OTC:IGXT) shares closed up 13.21% at $0.30 
Via Benzinga
Study Says Antidepressants Don’t Meaningfully Improve Depressed People’s Well-Being
Via Investor Brand Network
News headline image
Allied, ATAI Life Sciences Among Top Psychedelic Movers Of Today ↗
GAINERS: Allied (OTC:ALID) shares closed up 5.27% at $0.76 
Via Benzinga
News headline image
Compass Pathways, Small Pharma Among Top Psychedelic Movers Of Today ↗
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 8.17% at $9.80 
Via Benzinga
News headline image
April Update: Most Cannabis Categories Declined By More Than 20% ↗
The marijuana stock sector consists of 5 distinct categories and they each performed quite differently from one another in April.. 
Via Talk Markets
News headline image
Field Trip Health, Revive Therapeutics Among Top Psychedelic Movers Of Today ↗
GAINERS: Cybin (AMEX:CYBN) shares closed up 3.67% at $0.57 LOSERS: 
Via Benzinga
Vancouver Island University to Expand Psychedelic Mental Healthcare Program
Via Investor Brand Network
News headline image
Psychedelic Stock Gainers And Losers From April 28, 2022 ↗
GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 4.35% at $1.20 
Via Benzinga
BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Advancing Pipeline in Commitment to Transform Mental Health Treatment Landscape
Via Investor Brand Network
Colorado Patients Reap Benefits of Ketamine Treatments for Depression
Via Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Preclinical Data from CYB004 Study Showing Significant Advantages
Via Investor Brand Network
Oregon to Become the First State to Legally Roll Out Psilocybin
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 28, 2022 – Oregon is set to become the first US state to market legal psilocybin, the psychoactive substance found in... 
Via FinancialNewsMedia
Topics Derivatives ETFs
News headline image
Psychedelic Stock Gainers And Losers From April 27, 2022 ↗
GAINERS: Intelgenx Technologies (OTC:IGXT) shares closed up 3.77% at $0.28 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From April 26, 2022 ↗
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 3.61% at $0.29 
Via Benzinga
News headline image
Psychedelic Drug Patenting: Still Only Scratching The Surface ↗
Psychedelic drug R&D remains in its infancy, with dozens of psychedelics and several 
Via Talk Markets
Depression Causes Lasting Physiological Alterations to Immunity Cells
Via Investor Brand Network
News headline image
ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today ↗
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 3.97% at $4.97 
Via Benzinga
News headline image
Psyched: Big Pharma's Sanofi Enters Psychedelics Space, DNA From 80 Psilocybe Mushrooms Published Online, Maine Psychedelics Bill Shelved ↗
Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami... 
Via Benzinga
News headline image
Missed The Benzinga Psychedelics Capital Conference? Check Out Full Recording And Exclusive Coverage ↗
Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami... 
Via Benzinga
Three Kinds of Trauma Psychedelics Hope to Treat
Via Investor Brand Network
News headline image
Cybin Presents "Why Cybin Is Investing So Heavily On Developing Novel Psychedelic Molecules" At The Psychedelic Capital Conference ↗
Photo by Presetbase Lightroom Presets on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
News headline image
Field Trip Health, Mind Medicine Among Top Psychedelic Movers Of Today ↗
GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 3.49% at $0.87 
Via Benzinga
News headline image
Cybin's Major Depressive Disorder Treatment Trials Continue With Clinilabs Drug Development Corp ↗
Three weeks after announcing the results of its preclinical trials for CYB003, Cybin (NYSE:CYBN) made public a partnership with Clinilabs Drug Development Corporation to take the proprietary drug to... 
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
41 42 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today